J3M-MC-JZQB 4+
Medable, Inc.
Designed for iPhone
-
- Free
iPhone Screenshots
Description
Study for patients with KRAS G12C-Mutant, Metastatic Non-Small Cell Lung Cancer
A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression (TPS ≥ 50%). This app is specifically intended for participants in the J3M-MC-JZQB study only.
App Privacy
The developer, Medable, Inc., indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy.
Data Linked to You
The following data may be collected and linked to your identity:
- Health & Fitness
- Identifiers
- Diagnostics
Privacy practices may vary based on, for example, the features you use or your age. Learn More
Information
- Provider
- Medable, Inc.
- Size
- 105.2 MB
- Category
- Health & Fitness
- Compatibility
-
- iPhone
- Requires iOS 14.0 or later.
- iPod touch
- Requires iOS 14.0 or later.
- Mac
- Requires macOS 11.0 or later and a Mac with Apple M1 chip or later.
- Apple Vision
- Requires visionOS 1.0 or later.
- Languages
-
English, Afrikaans, Arabic, Assamese, Bengali, Bulgarian, Catalan, Cebuano, Croatian, Czech, Danish, Dutch, Estonian, Filipino, Finnish, French, Galician, Georgian, German, Greek, Gujarati, Haitian, Hebrew, Hiligaynon, Hindi, Hungarian, Iloko, Italian, Japanese, Kannada, Korean, Latvian, Lithuanian, Malay, Malayalam, Marathi, Norwegian Bokmål, Oriya, Pedi, Polish, Portuguese, Punjabi, Romanian, Russian, Serbian, Sesotho, Setswana, Simplified Chinese, Slovak, Slovenian, Spanish, Swedish, Tamil, Telugu, Thai, Traditional Chinese, Turkish, Ukrainian, Urdu, Vietnamese, Xhosa, Zulu
- Age Rating
- 4+
- Copyright
- © Medable, Inc.
- Price
- Free